ClinicalTrials.gg
CompletedNCT06575478Updated Oct 5, 2026Results posted

Evaluation of Fuling Yunhua Granules and Dihuang Baoyuan Granules in Drug Naive Type 2 Diabetes Patients

A Phase 2 interventional study of Fuling Yunhua Granules and Dihuang Baoyuan Granules in Diabetes Mellitus, Type 2, Diabetes and Type2diabetes, sponsored by Beijing Supreme Life Pharmaceutical Technology Co., Ltd.. Completed at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-10-05.

Sponsored by Beijing Supreme Life Pharmaceutical Technology Co., Ltd. · Phase 2, Interventional, and Treatment

Updated Oct 5, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
95
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 909 studies in Diabetes Mellitus, Type 2 with a site in China — 205 open to participants now, 228 under way, 46 of them phase 3. Diabetes Mellitus, Type 2 · China.

Enrollment
509th of 767
95 · median 199
Started
2024
with 82 others
Phase 2
61 of 909
14 open now
Registered
690th of 909
by date

Among the 909 studies in Diabetes Mellitus, Type 2 with a site in China, this one is the 509th largest by enrollment of the 767 interventional ones that give a count, is one of 83 that started in 2024, is one of 61 in phase 2, and was the 690th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

205 of the 909 studies in Diabetes Mellitus, Type 2 with a site in China are open now. Recruiting first, the newest first:

200 more — sign in →

All 205 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 909 studies in Diabetes Mellitus, Type 2 with a site in China, or all of them as a file.
02

Study summary

The goal of this investigator-initiated clinical trial is to investigate the efficacy and safety of sequential therapy of Fuling Yunhua Granules (prescription A) and Dihuang Baoyuan Granule (prescription B) in the treatment of type 2 diabetes patients with poor glycemic control after diet and exercise intervention.

Read the detailed description

This is a multicenter, randomized, double-blind, placebo-controlled study, including a up to 2-week screening period, a 1-week baseline period, a 12-week treatment period and a 1-week follow-up period.

72 participants who meet the enrollment requirements will enter the baseline period, during which 7 days of CGM data will be collected. After entering the treatment period, participants will be randomly assigned to prescription ABA group, prescription ABA-matched placebo group, prescription BAB group and prescription BAB-matched placebo group in a ratio of 2:1:2:1 and receive corresponding treatment.

It is expected that an interim analysis will be conducted after 30 participants have completed 4 weeks of treatment and 4 weeks of their data is obtained. Based on the CGM data of the participants in the 4th week of treatment, the change of TIR in the 4th week compared with the baseline will be analyzed, and the IDMC will make a decision based on the results of this analysis.

03

Conditions studied

  • Diabetes Mellitus, Type 2
  • Diabetes
  • Type2diabetes
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age 18-75 years (inclusive), male or female;
  2. Patients diagnosed with T2DM ≥ 8 weeks according to the 2020 WHO diagnostic criteria and classification;
  3. Have controlled blood sugar through diet and exercise for 3 months before screening and did not receive any hypoglycemic drugs, or used hypoglycemic drugs for no more than 2 weeks within 3 months before screening and did not use hypoglycemic drugs within 1 month before screening;
  4. (BMI) ≥ 19 kg/m2;
  5. (HbA1c) ≥ 7.0% and \< 10.5% at screening;
  6. Fasting plasma glucose (FPG) \< 13.9 mmol/L at screening;
  7. Able to understand the procedures and methods of this study, willing to strictly abide by the clinical research protocol to complete this study, and voluntarily sign the ICF

Exclusion criteria

Exclusion Criteria:

  1. Non-type 2 diabetes: type 1 diabetes, gestational diabetes, special types of diabetes;
  2. History of acute complications of diabetes within 6 months before screening (diabetic ketoacidosis, diabetic hyperglycemic hyperosmolar syndrome or lactic acidosis, etc.);
  3. History of chronic complications of diabetes with unstable condition or requiring treatment within 6 months before screening (proliferative retinal disease, severe diabetic neuropathy or intermittent claudication, etc.);
  4. Experienced more than 3 episodes of grade 3 hypoglycemia within 6 months before screening;
  5. Have used systemic (intravenous, oral or intra-articular) continuously or cumulatively for ≥ 7 days within 3 months before screening;
  6. Severe infection within 3 months before screening;
  7. Diagnosed with malignant tumors within 5 years before screening (except for cured basal cell carcinoma of the skin or carcinoma in situ of the cervix);
  8. Severe cardiovascular disease, such as heart failure ( [NYHA] grade III-IV), myocardial infarction, coronary artery bypass grafting or percutaneous coronary intervention, occurred within 6 months before screening, Sustained and arrhythmia (such as second- or third-degree atrioventricular block or prolongation ≥470 ms in men and ≥480 ms in women), acute coronary syndrome or or stroke wait;
  9. Suffering from diseases that may significantly affect drug absorption, distribution, metabolism and excretion within 6 months before screening: inflammatory bowel disease, peptic ulcer, history of gastrointestinal or rectal bleeding, history of important gastrointestinal surgery (such as : Gastrectomy, gastrointestinal anastomosis, or intestinal resection), etc.;
  10. Accompanied by thyroid dysfunction that cannot be controlled with stable drug dosage during screening;
  11. History of hypertension and take antihypertensive treatment regularly for more than 4 weeks but still have poor blood pressure control, with systolic blood pressure >160 mmHg and/or diastolic blood pressure >100 mmHg;
  12. History of organ transplantation or severe diseases in the past or present;
  13. History of clinically significant drug allergy or atopic allergic disease (asthma, urticaria, eczematous dermatitis);
  14. History of major surgery (intrathoracic, intracranial, abdominal, etc.) within 6 months before screening, or those who plan to undergo surgery during the study that may affect study completion or compliance;
  15. Any laboratory test meets any of the following criteria during screening:

    (ALT) or aspartate aminotransferase (AST) > (ULN) × 2.5 times (eGFR) calculated using the CKD-EPI formula \< 60 mL/min /1.73m2 Total (TBIL)>ULN×1.5 times Fasting triglyceride (TG)>5.7 mmol/L Fasting C-peptide \<0.8 ng/ml (or 0.26 nmol/L)

  16. Those who are positive for surface antigen during screening (except those whose quantitative test results of hepatitis B virus deoxyribonucleic acid [HBV-DNA] are lower than the lower limit of the detection reference range and who are not using anti-hepatitis B virus drugs during screening), or who are receiving anti-hepatitis B virus drug treatment , or those who are virus (HCV) antibody positive, or (HIV) antibody positive, or Treponema pallidum antibody positive;
  17. Blood donation or massive blood loss (>400 mL) within 3 months before screening;
  18. Pregnant or lactating women, or men or women of who plan to become pregnant during the study or are unwilling to take medically recognized measures;
  19. History of alcohol, tobacco addiction or drug abuse is known or suspected at the time of screening;
  20. Participated in any interventional drug clinical research within 3 months before screening;
  21. Allergic to study drugs and their ingredients;
  22. Participants who the researcher believes have any other factors that are inappropriate for participating in this study.
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
95 participants (actual)

Study arms

  • Experimental
    prescription ABA

    Fuling Yunhua Granules and Dihuang Baoyuan Granules

    Drug: Fuling Yunhua Granules

  • Experimental
    prescription BAB

    Fuling Yunhua Granules and Dihuang Baoyuan Granules

    Drug: Dihuang Baoyuan Granules

  • Placebo comparator
    prescription ABA-matched placebo/ BAB-matched placebo

    Fuling Yunhua Granules placebo and Dihuang Baoyuan Granules placebo

    Drug: Fuling Yunhua Granules matched placebo/Dihuang Baoyuan Granules matched placebo

Interventions

  • DrugFuling Yunhua Granules

    Fuling Yunhua Granules

    Also known as: prescription A

  • DrugDihuang Baoyuan Granules

    Dihuang Baoyuan Granules

    Also known as: prescription B

  • DrugFuling Yunhua Granules matched placebo/Dihuang Baoyuan Granules matched placebo

    Fuling Yunhua Granules placebo/Dihuang Baoyuan Granules placebo

    Also known as: prescription A matched placebo/B matched placebo

06

What researchers measure

Primary outcomes

  1. Change in HbA1c Concentrations (%) From Baseline

    Change in HbA1c concentrations (%) from baseline is the numerical difference between a participant's hemoglobin A1c (HbA1c) level at a specified follow-up time point(s) and their baseline level (initial assessment before intervention). HbA1c, a glycated hemoglobin biomarker, reflects average blood glucose over 8-12 weeks. Venous blood is collected via standard phlebotomy, and HbA1c is quantified using a laboratory-certified method (e.g., high-performance liquid chromatography \[HPLC\] or immunoassay) for accuracy. Calculated as: Follow-up HbA1c (%) - Baseline HbA1c (%), positive values mean increased average blood glucose, negative values mean decreased. This metric evaluates intervention efficacy (e.g., medications, lifestyle modifications) for glycemic control in diabetes or prediabetes populations.

    Time frame: 12 weeks

Secondary outcomes

  1. Change in FPG (mmol/L) From Baseline

    Change in Fasting Plasma Glucose (FPG) (mmol/L) from baseline is the numerical difference between a participant's FPG level at follow-up and their baseline FPG. FPG measures plasma glucose concentration after an 8-12 hour fast, reflecting overnight glycemic control. Venous blood samples are collected via standard phlebotomy, with glucose quantified using laboratory methods (e.g., hexokinase assay). Calculated as: Follow-up FPG (mmol/L) - Baseline FPG (mmol/L), positive values indicate increased fasting glucose, negative values a decrease. This metric assesses intervention efficacy in regulating fasting glycemia, critical for diabetes management.

    Time frame: 12 weeks

  2. The Proportion of Participants Who Achieved HbA1c Target

    The proportion of participants who achieved HbA1c target (HbA1c\<7.0% and \<6.5% Patient percentage)

    Time frame: 12 weeks

  3. Changes in TIR From Baseline

    Changes in Time in Range (TIR) from baseline refers to the difference between a participant's TIR at follow-up and their baseline TIR. TIR is the percentage of time blood glucose levels stay within a target range (typically 3.9-10.0 mmol/L \[70-180 mg/dL\] for most people with diabetes) over a specified period, measured via continuous glucose monitoring (CGM) devices. Calculated as: Follow-up TIR (%) - Baseline TIR (%), positive values indicate increased time in target range, negative values a decrease. This metric assesses glycemic stability and intervention effectiveness (e.g., medication adjustments, lifestyle changes) in managing blood glucose control.

    Time frame: 12 weeks

  4. Changes in TBR From Baseline

    Changes in Time Below Range (TBR) from baseline is the difference between a participant's TBR at follow-up and their baseline TBR. TBR is the percentage of time blood glucose levels fall below a target range (e.g., \<3.9 mmol/L \[70 mg/dL\] for adults) over a specified period, measured via continuous glucose monitoring (CGM). Calculated as: Follow-up TBR (%) - Baseline TBR (%), positive values indicate increased time below range, negative values a decrease. This metric evaluates risks of hypoglycemia and intervention impact on maintaining glucose above target levels.

    Time frame: 12 weeks

  5. Changes in TAR From Baseline

    Changes in Time Above Range (TAR) from baseline refers to the difference between a participant's TAR at follow-up and their baseline TAR. TAR is the percentage of time blood glucose levels exceed a target range (e.g., \>10.0 mmol/L \[180 mg/dL\] for most adults with diabetes) over a specified period, measured via continuous glucose monitoring (CGM). Calculated as: Follow-up TAR (%) - Baseline TAR (%), positive values indicate increased time above range, negative values a decrease. This metric assesses risks of hyperglycemia and intervention effectiveness in keeping glucose within target levels.

    Time frame: 12 weeks

  6. Changes in MAGE From Baseline

    Changes in Mean Amplitude of Glycemic Excursions (MAGE) from baseline is the difference between a participant's MAGE at follow-up and their baseline MAGE. MAGE quantifies the average magnitude of significant blood glucose fluctuations (exceeding a threshold, typically 1.4 mmol/L \[25 mg/dL\]) over a specified period, derived from continuous glucose monitoring (CGM) data. Calculated as: Follow-up MAGE - Baseline MAGE, higher values indicate greater glycemic variability, lower values more stable glucose. This metric evaluates intervention impact on reducing glucose swings, relevant for assessing glycemic stability in diabetes management.

    Time frame: 12 weeks

  7. Change From Baseline in Total Cholesterol (TC) at Week 12

    TTotal cholesterol (TC) was measured in venous blood samples and reported in mmol/L. Change from baseline was calculated as the TC value at Week 12 minus the baseline TC value. Negative values indicate a reduction in total cholesterol.

    Time frame: 12 weeks

  8. Change From Baseline in Body Weight at Week 12

    Body weight was measured in kilograms. Change from baseline was calculated as body weight at Week 12 minus baseline body weight. Negative values indicate weight loss, and positive values indicate weight gain.

    Time frame: 12 weeks

07

Results

Posted Oct 5, 2026

Participant flow

Participant flow — Overall Study
MilestonePrescription ABAPrescription BABPrescription Fuling Yunhua Granules Placebo/BAB-matched Placebo
Started323231
Completed263230
Not completed601

Outcome measures

PrimaryChange in HbA1c Concentrations (%) From Baseline

Change in HbA1c concentrations (%) from baseline is the numerical difference between a participant's hemoglobin A1c (HbA1c) level at a specified follow-up time point(s) and their baseline level (initial assessment before intervention). HbA1c, a glycated hemoglobin biomarker, reflects average blood glucose over 8-12 weeks. Venous blood is collected via standard phlebotomy, and HbA1c is quantified using a laboratory-certified method (e.g., high-performance liquid chromatography \[HPLC\] or immunoassay) for accuracy. Calculated as: Follow-up HbA1c (%) - Baseline HbA1c (%), positive values mean increased average blood glucose, negative values mean decreased. This metric evaluates intervention efficacy (e.g., medications, lifestyle modifications) for glycemic control in diabetes or prediabetes populations.

Time frame:
12 weeks
Reported as:
Mean · percentage of HbA1c
Change in HbA1c Concentrations (%) From Baseline
percentage of HbA1cPrescription ABAPrescription BABPrescription ABA/BAB-matched Placebo
Baseline HbA1c8.17 ± 0.7678.31 ± 1.0318.25 ± 0.819
HbA1c at Week 127.20 ± 0.9717.27 ± 0.9637.93 ± 1.004
SecondaryChange in FPG (mmol/L) From Baseline

Change in Fasting Plasma Glucose (FPG) (mmol/L) from baseline is the numerical difference between a participant's FPG level at follow-up and their baseline FPG. FPG measures plasma glucose concentration after an 8-12 hour fast, reflecting overnight glycemic control. Venous blood samples are collected via standard phlebotomy, with glucose quantified using laboratory methods (e.g., hexokinase assay). Calculated as: Follow-up FPG (mmol/L) - Baseline FPG (mmol/L), positive values indicate increased fasting glucose, negative values a decrease. This metric assesses intervention efficacy in regulating fasting glycemia, critical for diabetes management.

Time frame:
12 weeks
Reported as:
Mean · mmol/L
Change in FPG (mmol/L) From Baseline
mmol/LPrescription ABAPrescription BABPrescription ABA/BAB-matched Placebo
Baseline FPG9.048 ± 1.6289.583 ± 1.54319.149 ± 1.8092
FPG (mmol/L) after 12 weeks of treatment7.672 ± 1.30917.993 ± 1.62839.170 ± 2.0752
Relative change in FPG from baseline after 12 weeks of treatment (mmol/L)-1.463 ± 1.2551-1.590 ± 1.68090.027 ± 2.1562
SecondaryThe Proportion of Participants Who Achieved HbA1c Target

The proportion of participants who achieved HbA1c target (HbA1c\<7.0% and \<6.5% Patient percentage)

Time frame:
12 weeks
Reported as:
Count of participants · Participants
The Proportion of Participants Who Achieved HbA1c Target
ParticipantsPrescription ABAPrescription BABPrescription ABA-matched Placebo/ BAB-matched Placebo
HbA1c<7%at Week 1214133
HbA1c<6.5%at Week 12871
SecondaryChanges in TIR From Baseline

Changes in Time in Range (TIR) from baseline refers to the difference between a participant's TIR at follow-up and their baseline TIR. TIR is the percentage of time blood glucose levels stay within a target range (typically 3.9-10.0 mmol/L \[70-180 mg/dL\] for most people with diabetes) over a specified period, measured via continuous glucose monitoring (CGM) devices. Calculated as: Follow-up TIR (%) - Baseline TIR (%), positive values indicate increased time in target range, negative values a decrease. This metric assesses glycemic stability and intervention effectiveness (e.g., medication adjustments, lifestyle changes) in managing blood glucose control.

Time frame:
12 weeks
Reported as:
Mean · percentage of TIR
Changes in TIR From Baseline
percentage of TIRPrescription ABAPrescription BABPrescription Fuling Yunhua Granules Placebo/BAB-matched Placebo
Time in Range (TIR) Baseline52.59 ± 25.28746.26 ± 23.82156.13 ± 21.859
Time in Range (TIR)After 12 Weeks74.55 ± 23.37977.25 ± 25.2457.11 ± 63.99
Changes in TIR from baseline20.29 ± 29.82730.81 ± 26.159-0.42 ± 19.604
SecondaryChanges in TBR From Baseline

Changes in Time Below Range (TBR) from baseline is the difference between a participant's TBR at follow-up and their baseline TBR. TBR is the percentage of time blood glucose levels fall below a target range (e.g., \<3.9 mmol/L \[70 mg/dL\] for adults) over a specified period, measured via continuous glucose monitoring (CGM). Calculated as: Follow-up TBR (%) - Baseline TBR (%), positive values indicate increased time below range, negative values a decrease. This metric evaluates risks of hypoglycemia and intervention impact on maintaining glucose above target levels.

Time frame:
12 weeks
Reported as:
Mean · percentage of TBR
Changes in TBR From Baseline
percentage of TBRPrescription ABAPrescription BABPrescription ABA/BAB-matched Placebo
Time Below Range (TBR) Baseline0.37 ± 1.1450.13 ± 0.4790.13 ± 0.624
Time Below Range After 12 Weeks(TBR)0.35 ± 1.2210.46 ± 1.2610.38 ± 1.372
Changes in TBR from baseline0.08 ± 1.5690.32 ± 1.4020.36 ± 1.342
SecondaryChanges in TAR From Baseline

Changes in Time Above Range (TAR) from baseline refers to the difference between a participant's TAR at follow-up and their baseline TAR. TAR is the percentage of time blood glucose levels exceed a target range (e.g., \>10.0 mmol/L \[180 mg/dL\] for most adults with diabetes) over a specified period, measured via continuous glucose monitoring (CGM). Calculated as: Follow-up TAR (%) - Baseline TAR (%), positive values indicate increased time above range, negative values a decrease. This metric assesses risks of hyperglycemia and intervention effectiveness in keeping glucose within target levels.

Time frame:
12 weeks
Reported as:
Mean · percentage of TAR
Changes in TAR From Baseline
percentage of TARPrescription ABAPrescription BABPrescription ABA/BAB-matched Placebo
TAR Baseline47.04 ± 25.46053.61 ± 24.07343.74 ± 21.880
TAR After 12 Weeks25.09 ± 23.69522.29 ± 25.42742.51 ± 29.108
Changes in TAR from baseline-20.37 ± 30.113-31.12 ± 26.5310.05 ± 19.846
SecondaryChanges in MAGE From Baseline

Changes in Mean Amplitude of Glycemic Excursions (MAGE) from baseline is the difference between a participant's MAGE at follow-up and their baseline MAGE. MAGE quantifies the average magnitude of significant blood glucose fluctuations (exceeding a threshold, typically 1.4 mmol/L \[25 mg/dL\]) over a specified period, derived from continuous glucose monitoring (CGM) data. Calculated as: Follow-up MAGE - Baseline MAGE, higher values indicate greater glycemic variability, lower values more stable glucose. This metric evaluates intervention impact on reducing glucose swings, relevant for assessing glycemic stability in diabetes management.

Time frame:
12 weeks
Reported as:
Mean · mmol/l
Changes in MAGE From Baseline
mmol/lPrescription ABAPrescription BABPrescription ABA/BAB-matched Placebo
Baseline6.80 ± 2.1417 ± 1.6466.95 ± 1.816
After 12 Weeks5.3 ± 2.0164.95 ± 1.786.35 ± 1.414
Changes in MAGE from baseline-1.27 ± 1.896-2.01 ± 1.766-0.54 ± 1.645
SecondaryChange From Baseline in Total Cholesterol (TC) at Week 12

TTotal cholesterol (TC) was measured in venous blood samples and reported in mmol/L. Change from baseline was calculated as the TC value at Week 12 minus the baseline TC value. Negative values indicate a reduction in total cholesterol.

Time frame:
12 weeks
Reported as:
Mean · mmol/L
Change From Baseline in Total Cholesterol (TC) at Week 12
mmol/LPrescription ABAPrescription BABPrescription ABA/BAB-matched Placebo
Total Cholesterol at Baseline5.253 ± 1.05264.978 ± 0.99035.171 ± 0.9263
Total Cholesterol at Week 124.854 ± 1.03874.793 ± 0.85045.101 ± 1.1281
Change From Baseline at Week 12 from baseline-0.468 ± 0.6479-0.186 ± 0.7691-0.033 ± 0.8066
SecondaryChange From Baseline in Body Weight at Week 12

Body weight was measured in kilograms. Change from baseline was calculated as body weight at Week 12 minus baseline body weight. Negative values indicate weight loss, and positive values indicate weight gain.

Time frame:
12 weeks
Reported as:
Mean · kg
Change From Baseline in Body Weight at Week 12
kgPrescription ABAPrescription BABPrescription ABA-matched Placebo/ BAB-matched Placebo
Body Weight at Baseline69.20 ± 9.34773.53 ± 13.63469.39 ± 13.921
Body Weight at Week 1268.71 ± 9.67673.66 ± 13.92768.78 ± 13.858
Change From Baseline in Body Weight at Week 12-0.41 ± 2.0700.13 ± 1.678-0.54 ± 1.768

Adverse events

Collected over 12 Weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Prescription ABA0/32 (0%)1/32 (3.1%)24/32 (75%)
Prescription BAB0/32 (0%)0/32 (0%)19/32 (59.4%)
Prescription ABA-matched Placebo/ BAB-matched Placebo0/31 (0%)0/31 (0%)12/31 (38.7%)
Most frequent serious events
Most frequent serious events
EventPrescription ABAPrescription BABPrescription ABA-matched Placebo/ BAB-matched Placebo
Microvascular Coronary Artery DiseaseCardiac disorders1/320/320/31
Most frequent other events
Most frequent other events
EventPrescription ABAPrescription BABPrescription ABA-matched Placebo/ BAB-matched Placebo
diarrheaGastrointestinal disorders11/329/323/31
Abnormal liver functionHepatobiliary disorders6/322/321/31
Gastrointestinal distensionGastrointestinal disorders2/324/324/31
Urinary tract infectionsInfections and infestations4/320/323/31
NauseaGastrointestinal disorders3/323/320/31
Upper respiratory tract infectionsInfections and infestations3/321/321/31

Baseline characteristics

95 participants were randomly assigned to the 12-week treatment period (BAB regimen group, n=32; ABA regimen group, n=32; Placebo group, n=31)

Age, Continuous
Age, Continuous(years)Prescription ABAPrescription BABPrescription ABA/BAB-matched PlaceboTotal
Mean56.7 ± 11.5152.8 ± 9.6257.2 ± 8.7955.5 ± 10.14
Sex: Female, Male
Sex: Female, Male(Participants)Prescription ABAPrescription BABPrescription ABA/BAB-matched PlaceboTotal
Female17151446
Male15171749
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Prescription ABAPrescription BABPrescription ABA/BAB-matched PlaceboTotal
Asian32323195
Body Mass Index (BMI)
Body Mass Index (BMI)(kg/m^2)Prescription ABAPrescription BABPrescription ABA/BAB-matched PlaceboTotal
Mean25.03 ± 2.45926.58 ± 3.91125.20 ± 3.20225.61 ± 3.286
08

Study locations

1 site
  • Peking University People's Hospital
    Beijing, China
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — There is no plan to make individual participant data (IPD) available to other researchers.

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2024 to primary completion in Jan 2025, 5 months.

Results were first posted in Oct 2026, 1 year 8 months after primary completion.

Of 194 industry-sponsored phase 2 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 18. This study's 5 months is below that.

Counting every sponsor, half of 293 studies reached it within 15 months; a quarter within 11 and three quarters within 27.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 19, 2024
First posted
Aug 28, 2024
StartActual
Jul 31, 2024
Primary completionActual
Jan 27, 2025
CompletionActual
Jan 27, 2025
Results first posted
Oct 5, 2026
Last update
Oct 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Oct 5, 2026
Show all 1 update
  1. Oct 5, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT06575478
Lead sponsor
Beijing Supreme Life Pharmaceutical Technology Co., Ltd.
Responsible party
Sponsor
First posted
Aug 28, 2024
Start date
Jul 31, 2024
Primary completion
Jan 27, 2025
Completion
Jan 27, 2025
Results posted
Oct 5, 2026
Last update
Oct 5, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion